Your browser doesn't support javascript.
loading
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.
Pfister, Neil T; Fomin, Vitalay; Regunath, Kausik; Zhou, Jeffrey Y; Zhou, Wen; Silwal-Pandit, Laxmi; Freed-Pastor, William A; Laptenko, Oleg; Neo, Suat Peng; Bargonetti, Jill; Hoque, Mainul; Tian, Bin; Gunaratne, Jayantha; Engebraaten, Olav; Manley, James L; Børresen-Dale, Anne-Lise; Neilsen, Paul M; Prives, Carol.
Afiliação
  • Pfister NT; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Fomin V; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Regunath K; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Zhou JY; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Zhou W; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Silwal-Pandit L; Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radiumhospital, 0310 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway;
  • Freed-Pastor WA; Department of Biological Sciences, Columbia University, New York, New York 10027, USA; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA;
  • Laptenko O; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Neo SP; Quantitative Proteomics Group, Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research, Singapore S138673;
  • Bargonetti J; Department of Biological Sciences, Hunter College, City University of New York, New York, New York 10065, USA;
  • Hoque M; Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA;
  • Tian B; Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA;
  • Gunaratne J; Quantitative Proteomics Group, Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research, Singapore S138673; Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597;
  • Engebraaten O; The K.G. Jebsen Center for Breast Cancer Research, Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway; Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway;
  • Manley JL; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  • Børresen-Dale AL; Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radiumhospital, 0310 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway;
  • Neilsen PM; Swinburne University of Technology, Kuching 93350, Sarawak, Malaysia.
  • Prives C; Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
Genes Dev ; 29(12): 1298-315, 2015 Jun 15.
Article em En | MEDLINE | ID: mdl-26080815
ABSTRACT
Mutant p53 impacts the expression of numerous genes at the level of transcription to mediate oncogenesis. We identified vascular endothelial growth factor receptor 2 (VEGFR2), the primary functional VEGF receptor that mediates endothelial cell vascularization, as a mutant p53 transcriptional target in multiple breast cancer cell lines. Up-regulation of VEGFR2 mediates the role of mutant p53 in increasing cellular growth in two-dimensional (2D) and three-dimensional (3D) culture conditions. Mutant p53 binds near the VEGFR2 promoter transcriptional start site and plays a role in maintaining an open conformation at that location. Relatedly, mutant p53 interacts with the SWI/SNF complex, which is required for remodeling the VEGFR2 promoter. By both querying individual genes regulated by mutant p53 and performing RNA sequencing, the results indicate that >40% of all mutant p53-regulated gene expression is mediated by SWI/SNF. We surmise that mutant p53 impacts transcription of VEGFR2 as well as myriad other genes by promoter remodeling through interaction with and likely regulation of the SWI/SNF chromatin remodeling complex. Therefore, not only might mutant p53-expressing tumors be susceptible to anti VEGF therapies, impacting SWI/SNF tumor suppressor function in mutant p53 tumors may also have therapeutic potential.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Regulação Neoplásica da Expressão Gênica / Proteína Supressora de Tumor p53 / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Montagem e Desmontagem da Cromatina Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Regulação Neoplásica da Expressão Gênica / Proteína Supressora de Tumor p53 / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Montagem e Desmontagem da Cromatina Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article